FDA official announcements or Cambridge University press release

Researchers Develop Monoclonal Antibodies Against A. baumannii to Combat Antimicrobial Resistance

Sep 17, 2024, 09:00 AM

Researchers are exploring the use of monoclonal antibodies as a potential solution to tackle antimicrobial resistance, which could make infections untreatable in the future. Scientists at Cambridge University, including those at the Baker Lab, have developed monoclonal antibodies that show effectiveness against drug-resistant infections, specifically using engineered mice against A. baumannii. Prof. Stephen Baker highlighted the potential of this approach as a powerful new weapon. Additionally, machine-learning models for monoclonal antibody allocation during pandemics could reduce hospital cases by a third by targeting at-risk patients and those who would benefit most from treatments. This method may also alleviate reliance on broad-spectrum antimicrobials for treating infections.